Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.
Adenocarcinoma of Lung
/ drug therapy
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Female
Follow-Up Studies
Genetic Testing
/ statistics & numerical data
Health Status Disparities
Humans
Lung Neoplasms
/ drug therapy
Male
Molecular Targeted Therapy
/ mortality
Prognosis
Registries
/ statistics & numerical data
Retrospective Studies
Risk Factors
Smoking
/ adverse effects
Survival Rate
United States
American Indian or Alaska Native
/ statistics & numerical data
Guideline adherence
Health disparities
Informatics
Lung cancer mutation
NSCLC
Journal
Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
28
06
2019
revised:
28
09
2019
accepted:
15
10
2019
pubmed:
25
11
2019
medline:
6
7
2021
entrez:
25
11
2019
Statut:
ppublish
Résumé
American Indians and Alaska Natives (AI/AN) continue to experience extreme lung cancer health disparities. The state of Minnesota is home to over 70,000 AI/AN, and this population has a 2-fold increase in lung cancer mortality compared to other races within Minnesota. Genetic mutation testing in lung cancer is now a standard of high-quality lung cancer care, and EGFR mutation testing has been recommended for all adenocarcinoma lung cases, regardless of smoking status. However, genetic testing is a controversial topic for some AI/AN. We performed a multisite retrospective chart review funded by the Minnesota Precision Medicine Grand Challenge as a demonstration project to examine lung cancer health disparities in AI/AN. We sought to measure epidemiology of lung cancer among AI receiving diagnosis or treatment in Minnesota cancer referral centers as well as rate of EGFR testing. The primary outcome was the rate of EGFR mutational analysis testing among cases and controls with nonsquamous, non-small-cell lung cancer. We secured collaborations with 5 health care systems covering a diverse geographic and demographic population. We identified 200 cases and 164 matched controls from these sites. Controls were matched on histology, smoking status, sex, and age. In both groups, about one third of subjects with adenocarcinoma received genetic mutation testing. There was no significant difference in mutation testing in AI compared to non-AI controls at large health care systems in Minnesota. These data indicate that other factors are likely contributing to the higher mortality in this group.
Sections du résumé
BACKGROUND
American Indians and Alaska Natives (AI/AN) continue to experience extreme lung cancer health disparities. The state of Minnesota is home to over 70,000 AI/AN, and this population has a 2-fold increase in lung cancer mortality compared to other races within Minnesota. Genetic mutation testing in lung cancer is now a standard of high-quality lung cancer care, and EGFR mutation testing has been recommended for all adenocarcinoma lung cases, regardless of smoking status. However, genetic testing is a controversial topic for some AI/AN.
PATIENTS AND METHODS
We performed a multisite retrospective chart review funded by the Minnesota Precision Medicine Grand Challenge as a demonstration project to examine lung cancer health disparities in AI/AN. We sought to measure epidemiology of lung cancer among AI receiving diagnosis or treatment in Minnesota cancer referral centers as well as rate of EGFR testing. The primary outcome was the rate of EGFR mutational analysis testing among cases and controls with nonsquamous, non-small-cell lung cancer. We secured collaborations with 5 health care systems covering a diverse geographic and demographic population.
RESULTS
We identified 200 cases and 164 matched controls from these sites. Controls were matched on histology, smoking status, sex, and age. In both groups, about one third of subjects with adenocarcinoma received genetic mutation testing.
CONCLUSION
There was no significant difference in mutation testing in AI compared to non-AI controls at large health care systems in Minnesota. These data indicate that other factors are likely contributing to the higher mortality in this group.
Identifiants
pubmed: 31759888
pii: S1525-7304(19)30286-4
doi: 10.1016/j.cllc.2019.10.012
pmc: PMC7769592
mid: NIHMS1641139
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e164-e168Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002494
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
J Am Coll Radiol. 2017 Nov;14(11):1388-1395
pubmed: 29101972
J Environ Public Health. 2014;2014:321604
pubmed: 24669226
Am J Prev Med. 2018 Apr;54(4):568-575
pubmed: 29429606
Sci Rep. 2017 Jan 04;7:39721
pubmed: 28051122
Cancer. 2017 Dec 15;123 Suppl 24:5079-5099
pubmed: 29205305
Chest. 2017 Sep;152(3):587-597
pubmed: 28450031
MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1205-1211
pubmed: 27832052
Cancer. 2010 Oct 15;116(20):4810-6
pubmed: 20597131
Am J Public Health. 2016 Jul;106(7):1188-95
pubmed: 27077360
Cancer Control. 2016 Oct;23(4):338-346
pubmed: 27842323
J Natl Med Assoc. 2011 Aug;103(8):711-8
pubmed: 22046848
J Thorac Oncol. 2013 Jul;8(7):823-59
pubmed: 23552377
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Pharmacogenet Genomics. 2017 May;27(5):169-178
pubmed: 28181923
J Oncol Pract. 2019 Apr;15(4):e289-e299
pubmed: 30830833
Onco Targets Ther. 2017 Aug 29;10:4295-4303
pubmed: 28919778
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
J Health Care Poor Underserved. 2019;30(2):431-441
pubmed: 31130528
Lung Cancer. 2018 Oct;124:53-64
pubmed: 30268480
Risk Anal. 2012 Jul;32 Suppl 1:S69-84
pubmed: 22882894